TherOx is now a part of the ZOLL Medical family.

Attending TCT? Come to our breakfast symposium:
SuperSaturated Oxygen in STEMI to Reduce Infarct Size: A New FDA Approved Therapy
Moderated by Gregg W. Stone, M.D.
Thursday, September 26, 2019 – 6:30 a.m. – 7:45 a.m. • Room 215, Level 2, Moscone South

Add to Calendar
Visit us at booth #1852 to learn more about SSO2 Therapy.

SSO2 Improves on Stenting Outcomes1,2

Median Infarct Size Reduction vs. PCI Alone*

Anterior ≤ 6 hour
n=382
Anterior ≤ 3 hour
n=169
Pre-PCI TIMI II/III
n=78
IS reduction beyond PCI

*96.9% posterior probability of superiority
1 Stone, et al. Circ Cardiovasc Interv. 2009 Oct; 2:366-375.
2 AMIHOT II subset data on file at TherOx. Inc.

“Infarct size…is strongly associated with all-cause mortality and hospitalization of HF within 1 year.”

Stone, et al. JACC. Vol. 67, No. 14, 1674-84. 2016.

Our Technology

TherOx has developed proprietary technology to prepare and safely deliver a hyperbaric infusate of oxygen locally to ischemic (oxygen deficient) tissue for improved patient outcomes.

SSO2 Therapy

SSO2 Therapy is a novel treatment designed to minimize damage to heart tissue following the most serious heart attacks (LAD STEMI).

Contact TherOx

Caution: Federal (United States) law restricts this device to sale by or on the order of a physician.
The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.